Healthcare Stock Alert! 1:1 Bonus Shares, Record Date This Week; A Profitable Bet?

One of India's top Contract Research and Testing Organizations (CRTOs), Vimta Labs provides a broad variety of services to a number of sectors, including electronics, food, and pharmaceuticals. Vimta Labs has a network of diagnostic facilities and labs throughout India in addition to a sizable laboratory facility. VIMTA provides a broad range of services as a full-service contract research and testing organization.

Vimta Labs Bonus Shares

"We hereby inform you that the shareholders have approved, issue of bonus equity shares in the proportion of 1:1, i.e., 1 (One) bonus equity share of Rs 2/ each for every 1 (One) fully paid-up equity share held as on the record date i.e., on 13th June 2025," said Vimta Labs in a stock exchange filing.

"The Board of Directors has fixed Friday, 13th June 2025 as the Record Date for the purpose of determining the equity shareholders of the Company eligible for bonus equity shares of the Company," Vimta Labs confirmed in a regulatory filing.

Vimta Labs Financials

Vimta Labs' net profit climbed 48.34% to Rs 18.32 crore in the March 2025 quarter from Rs 12.35 crore in the March 2024 quarter. Compared to Q4FY24, which ended in March 2024, when sales were Rs 72.73 crore, they increased 29.85% to Rs 94.44 crore in Q4FY25. The net profit for the entire year improved 64.20% to Rs 67.34 crore in March 2025 compared to Rs 41.01 crore in March 2024.

In the year ending in March 2025, sales surged 19.19% to Rs 343.98 crore, compared to Rs 288.60 crore in the year ending in March 2024. With an EBITDA of Rs 126.2 cr, the firm maintained high operating margins. With total debt of only Rs 8.5 cr and cash and equivalents of Rs 32.9 cr, Vimta ended the year in a net debt-free position. The basic EPS for Q4 was Rs 8.2, while the EPS for the year was Rs 30. In anticipation of additional revenue streams starting in Q1 FY27, the company is spending Rs 40 cr in biologics CR&D facilities.

Vimta Labs Share Price Target

"Vimta Labs stock price is bearish on the Daily charts with strong resistance at 1020. A Daily close below support of 918 could lead to a target of 805 in the near term," commented A R Ramachandran, independent research analyst.

Disclaimer

The recommendations made above are by market analysts and are not advised by either the author, nor Greynium Information Technologies. The author, nor the brokerage firm nor Greynium would be liable for any losses caused as a result of decisions based on this write-up. Goodreturns.in advises users to consult with certified experts before making any investment decision.